Clinical Trial Update: Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients

View source ↗

Summary

The trial evaluated expression of HPGD and SCLO2A1 in patients with Clear Cell Renal Cell Carcinoma and is marked as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Snippet

Sponsor: Shang Panfeng | Conditions: Clear Cell Renal Cell Carcinoma (ccRCC) | Status: COMPLETED